On-Demand Webinar

Drug approvals in the age of COVID-19

Tips for navigating the rapidly changing regulatory landscape now and in a post-pandemic world.

BLAINE VAN LEUVEN
CMC Regulatory Director
Clarivate
ANA EZQUERRO
Senior Regulatory Solutions Consultant, EU and RoW
Clarivate

In 2020, the global pharmaceutical industry united with one purpose: to combat the COVID-19 pandemic. Multiple countries responded to the need for COVID-19 vaccines with new rules that would expedite the clinical trials process and get the vaccines to market as fast as possible.

These unprecedented regulatory changes will undoubtedly alter the process and speed of drug and vaccine approvals forever. How can you monitor and keep track of changing chemistry, manufacturing, and controls (CMC) requirements and drug development regulations to ensure your drugs meet the new guidelines, get regulatory approval and are safely delivered to patients?